Capital Building in Washington DC

Advocacy & Policy

To improve patient care, ASCO advocates for increased federal funding for research, greater health care access, value in cancer care, and payment reform.

  • ASCO Weighs in on CAP Demo in Drug Pricing Proposal

    The International Pricing Index Model (IPI) for Medicare Part B drugs proposes sweeping reforms that would, in part, benchmark some Medicare Part B drug prices against other countries and change how providers get paid for administering drugs to patients.

    Learn More
  • New Standards for Safe Handling of Hazardous Drugs

    ASCO’s standards largely endorse best practices issued by other stakeholder groups for safely handling hazardous drugs but offer alternatives in several key areas where more research is needed to identify evidence-based safety measures.

    Learn More
  • 2019 Medicare Physician Fee Schedule and QPP Rule

    In the latest ASCO in Action podcast, ASCO CEO Dr. Clifford A. Hudis discusses the changes made to the physician fee schedule and the Quality Payment Program (QPP), and what this may mean for your oncology practice.

    Learn More

Random Quote

"I value the broad exposure ASCO affords my specialty throughout the oncology world. All of us have the opportunity to learn about the latest advances in our field and to broadly share our own research."
Clifford Hudis, MD, FASCO
ASCO CEO